Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 17:52 ET | Source: Zelluna ASA

Zelluna ASA - Successful private placement and retail offering

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the...
November 03, 2025 10:47 ET | Source: Zelluna ASA

Zelluna ASA – Contemplates private placement

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR...
November 03, 2025 10:39 ET | Source: Zelluna ASA

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its...
October 09, 2025 01:58 ET | Source: Zelluna ASA

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK

On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a...
September 10, 2025 02:00 ET | Source: Zelluna ASA

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an...
August 20, 2025 01:00 ET | Source: Zelluna ASA

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its...
August 14, 2025 06:00 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a...
July 03, 2025 06:07 ET | Source: Zelluna ASA

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to...
June 25, 2025 10:19 ET | Source: Zelluna ASA

Disclosure of share transfer from Inven2 AS

Issuer: Zelluna ASAISIN: NO0013524942Date of transaction: 25 June 2025 Inven2 AS, a major shareholder in Zelluna ASA, has transferred a total of 120,796 shares in Zelluna ASA to two inventors, in...
May 27, 2025 07:52 ET | Source: Zelluna ASA

Disclosure of Shareholding – Gjelsten Holding AS

Issuer: Zelluna ASAISIN: NO0013524942Date of event triggering the notification: 27 May 2025Threshold crossed: 5% In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding...